Jose Matus, MD
Neurology · Sherman, TXNPI 1841298270
Payments from drug & device makers
Across 34 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83
- Boston Scientific$79
- Amgen$74
- SK Life Science, Inc.$65
- Supernus Pharmaceuticals, Inc.$52
- MDD US Operations, LLC$51
- plus $376 from 14 others
What the payments were for
- Food & beverage$781100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $83 |
| Boston Scientific | 1 | $79 |
| Amgen | 3 | $74 |
| SK Life Science, Inc. | 2 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| MDD US Operations, LLC | 3 | $51 |
| Novartis | 2 | $50 |
| Abbott | 2 | $45 |
| AstraZeneca | 2 | $44 |
| UCB, Inc. | 2 | $41 |
| Eisai Inc. | 1 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Livanova USA, Inc. | 1 | $15 |
How this compares
$781 in reported general payments places this provider in the 35th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 21 | $1,024 |
| Primidone | 33 | $951 |
| Verapamil Er PmVerapamil Hcl | 13 | $570 |
| Memantine Hcl | 25 | $469 |
| RivastigmineRivastigmine Tartrate | 11 | $469 |
| Gabapentin | 30 | $318 |
| Propranolol Hcl ErPropranolol Hcl | 16 | $308 |
| Lisinopril | 20 | $306 |
| Valproic AcidValproic Acid (As Sodium Salt) | 12 | $290 |
| Amitriptyline Hcl | 17 | $243 |
| Nortriptyline Hcl | 16 | $206 |
| Topiramate | 13 | $149 |
| ClopidogrelClopidogrel Bisulfate | 11 | $139 |
| Donepezil Hcl | 16 | $128 |
| Escitalopram Oxalate | 20 | $127 |
Paid to pharmacies, not to this prescriber.
Other neurology in Sherman
- Bharathy SundaramSherman$7.2M
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
- Susan IannacconeDallas$5.1M
- Benjamin GreenbergDallas$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.